NAT10 and colorectal carcinoma: Given the role of NAT10 in driving DKK2 secretion to suppress CD8+ T cell function within the CRC microenvironment, we evaluated whether inhibiting NAT10 or neutralizing DKK2 could potentiate immune checkpoint blockade (ICB) efficacy.